MARKET

CSTL

CSTL

Castle Biosciences
NASDAQ
23.55
+0.02
+0.09%
After Hours: 23.55 0 0.00% 16:10 03/30 EDT
OPEN
23.54
PREV CLOSE
23.53
HIGH
23.92
LOW
23.24
VOLUME
286.41K
TURNOVER
--
52 WEEK HIGH
44.28
52 WEEK LOW
14.59
MARKET CAP
700.17M
P/E (TTM)
-28.2577
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CSTL last week (0323-0327)?
Weekly Report · 16h ago
Castle Biosciences to present new data from DecisionDx-Melanoma test at AAD
TipRanks · 3d ago
Castle Biosciences To Present New Data Showing DecisionDx-Melanoma Test Refines Mortality Risk Within AJCC Stages For Patients With Cutaneous Melanoma At 2026 AAD Annual Meeting
Benzinga · 3d ago
Castle Biosciences shares rise; DecisionDx-Melanoma study in 1,868 SEER-linked patients shows 5-year melanoma-specific survival of 96.7% for Class 1A vs 70.0% for Class 2B in T1 tumors
Reuters · 3d ago
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
PR Newswire · 3d ago
Weekly Report: what happened at CSTL last week (0316-0320)?
Weekly Report · 03/23 09:51
Castle Biosciences CEO Derek J. Maetzold disposes of USD 500,438 in common shares
Reuters · 03/19 20:22
Castle Biosciences CEO Derek J. Maetzold disposes of USD 784,000 in common shares
Reuters · 03/17 20:38
More
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

Webull offers Castle Biosciences Inc stock information, including NASDAQ: CSTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CSTL stock methods without spending real money on the virtual paper trading platform.